核酸适体在癌症诊疗中的研究进展

核酸适体是通过体外筛选技术得到的可特异性结合靶标分子的单链寡核苷酸分子探针,其表现出与抗体相当或更优异的特异性和亲和力,且具有靶标范围广、免疫原性低、易于精准制备和修饰及设计灵活可控等优势.为癌症的早期筛查、诊断及靶向治疗提供了全新的分子工具,在癌症诊疗领域获得了广泛的关注与应用.本文聚焦核酸适体在癌症诊断及治疗中的应用,对近年来取得的研究进展进行了系统性总结,并对未来发展方向及前景进行了展望.     

核酸适体偶联药物的生物偶联构建技术与应用

核酸适体被称为“化学抗体”, 具有与抗体类似或更加优异的特异性和亲和力, 可以精准地靶向靶蛋白, 与靶蛋白特异性结合. 此外, 核酸适体还具有获取简单、 合成简便、 易于进行化学修饰、 不易变性、 靶标范围广、 免疫原性低及细胞内化快等优点, 已被广泛应用于众多研究领域. 在癌症治疗领域, 核酸适体作为一种优异的靶向识别工具和药物递送载体, 可实现抗肿瘤药物的精准递送. 将核酸适体与药物分子偶联, 可通过核酸适体的靶向作用使药物分子随核酸适体共同进入靶细胞, 实现药物分子在靶细胞内的富集, 进而促进靶细胞的死亡. 近年来, 核酸适体偶联药物已成为癌症靶向治疗的前沿新兴领域, 希望通过该领域的深入研究为癌症靶向治疗领域提供新思路. 本文综合评述了以生物偶联技术构建的核酸适体偶联药物及其应用研究.     

适体功能化的金纳米棒用于癌症靶向治疗的研究进展

金纳米棒(gold nanorods,GNRs)具有特殊的光学性质、较大的比表面积、出色的光热转换性能、表面易修饰等特点,在药物递送、光疗、生物成像和化学传感等领域应用十分广泛。适体是短的单链DNA或RNA片段,可特异性识别癌细胞或其表面的膜蛋白。近年来,适体功能化的GNRs在癌症靶向治疗领域显示出良好的应用前景。根据GNRs对癌症作用机制的差异,本文从光热疗法、光动力疗法、化疗和联合疗法4个方面总结了适体功能化的GNRs在癌症靶向治疗中的最新进展,并对该领域面临的主要挑战和发展趋势进行了探讨与展望。     

核酸适体靶向的膜蛋白识别与功能调控研究进展

膜蛋白在细胞生命活动中发挥着重要作用, 研究并调控细胞膜蛋白的结构和功能有助于阐明生命活动的基本规律, 为新型药物研发和高效疾病诊治提供研究基础. 核酸适体是一类特殊的寡核苷酸序列, 因具有特异性识别靶标的能力而被广泛用于生物传感领域. 将核酸适体与DNA纳米技术相结合, 利用DNA分子可程序化设计、 可功能化修饰等优势, 发展核酸适体靶向的膜蛋白识别与功能调控方法可为研究膜蛋白相互作用提供有力工具. 本文介绍了基于核酸适体靶向识别的DNA纳米技术在膜蛋白识别及细胞功能调控中的研究进展, 并对核酸适体靶向的膜蛋白识别及功能调控领域面临的挑战进行了分析, 对其应用前景进行了展望.     

基于cell-SELEX的核酸适配体-纳米材料复合物用于癌细胞检测研究进展

发展高灵敏、高选择性的癌细胞检测方法是实现癌症的早期诊断和治疗的关键.基于cell-SELEX（指数富集配体系统进化法）新技术筛选出的核酸适配体,因其对癌细胞的高亲和力和高特异性,以及体积小、免疫原性小、易于进行化学修饰等优点,已被广泛应用于癌细胞的检测.此外,核酸适配体与纳米材料,包括金属纳米粒子、量子点、纳米二氧化硅和碳纳米材料等结合后,将会增强其对癌细胞的识别能力.本文综述了近年来基于cell-SELEX技术筛选出的核酸适配体与纳米材料结合所形成的复合物作为新型分子工具用于增强癌细胞识别和检测的研究进展,并对此领域的未来发展作了展望.     

核酸适体在生物医学中的应用

核酸适体是经配体指数富集系统进化技术（SELEX）筛选获得的一类能够特异性地结合离子、分子,甚至整个细胞的单链DNA或者RNA分子。本文介绍了核酸适体及相关筛选技术SELEX;综述了近年来以提高筛选效率和效果为目标的核酸适体筛选技术新进展;列举了核酸适体在无机离子、小分子、生物大分子和肿瘤细胞检测、肿瘤标记物的发现等方面的应用;讨论了基于核酸适体的靶向治疗策略;最后对核酸适体在生物医学上的应用前景进行了展望。     

基于核酸适体与互补核酸和目标蛋白之间竞争反应的PDGF蛋白特异性识别

报道了一种利用核酸适体与互补核酸和目标蛋白之间的竞争反应用于PDGF蛋白的特异性识别方法.采用反相微乳液技术制备了包覆有亚甲基蓝(MB)的SiO2纳米复合物(SiO2-MB),利用固定在磁性纳米颗粒上的核酸适体与SiO2-MB纳米颗粒标记的互补核酸进行杂交反应,将一定数量的SiO2-MB纳米颗粒固定于磁性纳米颗粒的表面...     

核酸适配体在肿瘤靶向治疗方面的研究进展

传统的抗肿瘤药物大多不具有选择性,在临床治疗中产生了严重的毒副作用。核酸适配体是一种小分子核酸,能够与靶标高亲和性、高特异性地结合。选择与癌症发生发展过程密切相关的生物标记物为靶标进行SELEX过程筛选出的核酸适配体自身可作为药物,也可与药物、siRNA、纳米粒等结合构成靶向给药体系,该体系能靶向作用于特定的肿瘤细胞,降低对正常细胞的毒性,用药量显著降低,药效提高。本文综述了近年来核酸适配体直接作为抗肿瘤药物、药物载体、siRNA载体以及作为纳米材料靶向剂构成多元复合靶向给药体系在肿瘤靶向治疗领域的研究进展。     

基于核酸适体的外泌体分子识别研究进展

自研究者证实外泌体承担了细胞外RNA等物质的运输功能以来, 关于外泌体来源与功能的研究一直备受关注. 近年来外泌体被发现具有作为疾病生物标志物的潜力, 使得拥有特定表面蛋白以及特定装载物的外泌体成为分析化学领域有价值的检测对象. 从化学本质角度来说, 外泌体的获取与分析需要依赖特异性的分子识别过程. 核酸适体作为分子识别单元, 因其特异性强、 亲和力高、 生物活性稳定、 易于合成和保存、 而且其序列和结构上具有可编程性, 易于设计和修饰, 已成功地用在外泌体相关的生物传感体系中. 本文从外泌体的化学组成及其具有生理、 病理意义的组分出发, 从外泌体通用生物标志物识别、癌细胞来源外泌体的检测及外泌体蛋白谱的分析这3个方面综述了以核酸适体作为分子识别单元在外泌体分析领域的代表性工作, 总结了现有的靶向外泌体的核酸适体序列信息以及应用场景, 阐述了利用化学合成与修饰以及DNA自组装等化学调控手段增强核酸适体分子识别性能的最新进展, 并从适用于外泌体分子识别的核酸适体的筛选以及化学修饰的角度, 对未来的研究方向进行了展望.     

基于核酸适体的电化学生物传感器*

核酸适体是一类体外筛选的、可与目标分子高效、高特异亲合的RNA或DNA寡核苷酸片段,与常规识别分子（如抗体等）相比,核酸适体作为一类新型识别分子具有明显特色和优势,已被广泛应用于生物传感等分子识别和应用研究领域。本文就基于核酸适体的电化学生物传感器（标记型和非标记型）的近期进展作简要评述,包括适体简介、标记型（“信号衰减”型、“信号增强”型、酶标记型和纳米粒子标记型）和非标记型电化学适体生物传感器等内容。     

适配体在癌症诊断与靶向治疗中的研究进展

核酸适配体是利用体外筛选技术,即指数富集的配体系统进化技术(SELEX),从核酸分子文库中得到的寡核苷酸片段。其与靶标物有很高的特异性和亲和力,将适配体作为识别单元的生物传感研究以及适配体偶联成像试剂的生物体内外成像研究在临床诊断中有很大的应用前景,此外,适配体靶向癌细胞或组织的治疗方法相比传统化学治疗副作用更小,在临床上也有极大的应用前景。本文综述了适配体目前在癌症诊断和靶向治疗两个方面的研究进展,并分析现阶段存在的问题以及面临的挑战。     

Carbon Nanomaterials for Targeted Cancer Therapy Drugs: A Critical Review

Cancer represents one of the main causes of human death in developed countries. Most current therapies, unfortunately, carry a number of side effects, such as toxicity and damage to healthy cells, as well as the risk of resistance and recurrence. Therefore, cancer research is trying to develop therapeutic procedures with minimal negative consequences. The use of nanomaterial‐based systems appears to be one of them. In recent years, great progress has been made in the field using nanomaterials with high potential in biomedical applications. Carbon nanomaterials, thanks to their unique physicochemical properties, are gaining more and more popularity in cancer therapy. They are valued especially for their ability to deliver drugs or small therapeutic molecules to these cells. Through surface functionalization, they can specifically target tumor tissues, increasing the therapeutic potential and significantly reducing the adverse effects of therapy. Their potential future use could, therefore, be as vehicles for drug delivery. This review presents the latest findings of research studies using carbon nanomaterials in the treatment of various types of cancer. To carry out this study, different databases such as Web of Science, PubMed, MEDLINE and Google Scholar were employed. The findings of research studies chosen from more than 2000 viewed scientific publications from the last 15 years were compared.     

Polyoxometalate-Based Nanomaterials Toward Efficient Cancer Diagnosis and Therapy

As an emerging class of inorganic metal oxides, organically functionalized polyoxometalates (POMs) or POM-based nanohybrids have been demonstrated promising potential for the inhibition of various cancer types by the virtue of their diversity in structures and significantly reduced toxicity. This contribution summarizes the latest achievement of POM-based nanomaterials in cancer diagnosis and various therapeutics to put forward our fundamental viewpoints on the design principles of modified POMs based on their application. In addition, major challenges and perspectives in this field are also discussed. We expect that this review will provide a valuable and systematic reference for the further development of POM-based nanomaterials.     

铋基纳米材料在癌症成像诊断与治疗中的应用

随着纳米医学的快速发展,纳米诊疗材料因其兼具诊断和治疗等多功能性而受到越来越多的关注.铋(Bi)基纳米材料具有优异的光学、电学和磁学性质,在肿瘤的诊疗一体化领域具有广阔的应用前景.我们总结了Bi基纳米材料常用的构建方法,重点介绍了其在计算机断层扫描(CT)成像、光声(PA)成像、放射疗法(RT)、光热疗法(PTT)及协...     

Multivalent Aptamer-modified DNA Origami as Drug Delivery System for Targeted Cancer Therapy

In spite of great development in nanoparticle-based drug delivery systems(DDSs)for improved therapeutic efficacy,it remains challenging for effective delivery of chemotherapeutic drugs to targeted tumor cells.In this work,we report a triangle DNA origami as targeted DDS for cancer therapy.DNA origami shows excellent biocompatibility and stability in cell culture medium for 24 h.In addition,the DNA origami structures conjugated with multivalent aptamers enable for efficient delivery of anticancer drug doxorubicin(Dox)into targeted cancer cell due to their targeting function,reducing side effects associated with nonspecific distribution.Moreover,we also demonstrated that the multivalent aptamer-modified DNA origami loading Dox exhibits prominent therapeutic efficacy in vitro.Accordingly,this work provides a good paradigm for the development of DNA origami nanostructure-based targeted DDS for cancer therapy.     

A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy

Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy.     

脱氧核糖核酸甲基化分析方法在肿瘤诊断和治疗中的应用

脱氧核糖核酸( DNA)甲基化是表观遗传改变的主要作用方式,在基因表达调控、基因组印迹、胚胎发育、维持正常细胞功能等过程中起着极其重要的作用;异常甲基化可以导致肿瘤的发生、发展.因此,探讨甲基化形成与改变的可能机制,建立准确性好、灵敏度高、操作简单的DNA甲基化分析方法,可为某些肿瘤的早期诊断提供重要依据.本文综述了D...     

Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

Biomimetic nanoparticles have recently emerged as a novel drug delivery platform to improve drug biocompatibility and specificity at the desired disease site, especially the tumour microenvironment. Conventional nanoparticles often encounter rapid clearance by the immune system and have poor drug-targeting effects. The rapid development of nanotechnology provides an opportunity to integrate different types of biomaterials onto the surface of nanoparticles, which enables them to mimic the natural biological features and functions of the cells. This mimicry strategy favours the escape of biomimetic nanoparticles from clearance by the immune system and reduces potential toxic side effects. Despite the rapid development in this field, not much has progressed to the clinical stage. Thus, there is an urgent need to develop biomimetic-based nanomedicine to produce a highly specific and effective drug delivery system, especially for malignant tumours, which can be used for clinical purposes. Here, the recent developments for various types of biomimetic nanoparticles are discussed, along with their applications for cancer imaging and treatments.